Map a competitive landscape

Name a therapeutic class or drug program and Anara maps where each therapy stands in the published evidence, where differentiation is real, and where patent or LOE timelines create risk. Use it for payer positioning, MSL preparation, or BD diligence.

Prompt

A medical affairs scientist builds a competitive position for an anti-PD-1 program, one tumor type per session.

I am building a competitive evidence position for our anti-PD-1 antibody program in second-line non-small cell lung cancer. The relevant comparators are pembrolizumab, nivolumab, and atezolizumab.

For each comparator, please find and synthesize the following from published trial data and current clinical guidelines:
- Key pivotal trials: study name, primary endpoint, reported OS and PFS data, patient population
- Current guideline recommendations: NCCN and ESMO, line of therapy, biomarker requirements
- Evidence gaps: indications where the competitor has limited or no head-to-head data
- LOE and patent protection signals: any publicly reported timeline information

Use papers in my library first, then search PubMed and ClinicalTrials.gov for anything not already uploaded. Cite every data point.

What to add to your library

• Required: the therapeutic class or drug program and the comparators to include.
• Required: your published trial papers, if you have them. Anara searches the library first, then academic databases and trial registries.
• Optional: the purpose driving the analysis, such as payer positioning, MSL preparation, or BD diligence.
• Optional: the indication or tumor type, if the analysis is indication-specific.

What you get

• A structured evidence brief for each comparator, with a citation for every data point.
• A synthesis of where differentiation is supported by data, where it is claimed but not established, and where gaps create risk or opportunity.
• A starting evidence position for the MSL team, payer meeting, or BD conversation.

Follow-ups

Dig into one comparator's evidence gap.

You identified that nivolumab has limited published data in the PD-L1-negative subgroup in second-line NSCLC. Search PubMed and ClinicalTrials.gov for any ongoing or completed trials in this subgroup. What is the current trial landscape? When might data emerge?

Update the brief after a new readout.

A new Phase 3 readout for pembrolizumab in second-line NSCLC was published last week. The DOI is [doi]. Update the relevant section of the competitive brief with the new data and tell me what changed in the competitive position.

Tips

• Name the clinical question before the comparators. Payer positioning and tumor board preparation produce different outputs.
• Run multi-indication programs one indication per session for enough depth.
• Anara has no access to unpublished data or internal competitor intelligence, and LOE timelines may differ by jurisdiction. Verify before stating externally.
• Treat the brief as an internal working document until medical affairs, legal, and regulatory review it.